It acts via AMP-activated protein kinase (AMPK), whose activation is required for metformin’s inhibitory effect on hepatic glucose production via inhibition of the diabetes-mediated activation of the gluconeogenic genes phosphoenolpyruvate carboxykinase and glucose-6-phosphatase [62-64]. Here, G6PC1 is linked to diabetes mellitus.